To demonstrate the implication of the 5-HT1A receptor as a target for the treatment of anxiety disorders, a study by [28] demonstrated that the activation of serotonergic terminals in the dorsal part of the bed nucleus of the stria terminalis (dBNST) reduces anxiety, while inhibition of these terminals produces anxiogenic effect. This evidence concerns the gene HTR1A and anxiety disorder.